Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEADFAST: Vildagliptin vs Gliclazide in Muslim T2DM Patients During Ramadan
NCT01758380Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2013
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 4, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novartis. Primary endpoint: Percentage of patients experiencing at least one Hypoglycaemic Event (HE) at 1 month. Started Jan 2013; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01758380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01758380.